Found: 58
Select item for more details and to access through your institution.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
- Published in:
- BMC Ophthalmology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12886-023-03012-1
- By:
- Publication type:
- Article
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
- Published in:
- BMC Ophthalmology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12886-023-03012-1
- By:
- Publication type:
- Article
Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3410, doi. 10.1111/dom.15203
- By:
- Publication type:
- Article
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0125164
- By:
- Publication type:
- Article
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
- Published in:
- European Heart Journal, 2024, v. 45, n. 13, p. 1173, doi. 10.1093/eurheartj/ehad889
- By:
- Publication type:
- Article
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 16, p. 1408, doi. 10.1093/eurheartj/ehad144
- By:
- Publication type:
- Article
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
- Published in:
- European Heart Journal, 2022, v. 43, n. 18, p. 1715, doi. 10.1093/eurheartj/ehac056
- By:
- Publication type:
- Article
reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.
- Published in:
- European Heart Journal, 2021, v. 42, n. 47, p. 4865, doi. 10.1093/eurheartj/ehab760
- By:
- Publication type:
- Article
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
- Published in:
- European Heart Journal, 2020, v. 41, n. 24, p. 2248, doi. 10.1093/eurheartj/ehz809
- By:
- Publication type:
- Article
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2019, v. 40, n. 33, p. 2801, doi. 10.1093/eurheartj/ehz299
- By:
- Publication type:
- Article
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
- Published in:
- European Heart Journal, 2011, v. 32, n. 20, p. 2541, doi. 10.1093/eurheartj/ehr334
- By:
- Publication type:
- Article
The future of clinical trials in secondary prevention after acute coronary syndromes.
- Published in:
- European Heart Journal, 2011, v. 32, n. 13, p. 1583
- By:
- Publication type:
- Article
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events.
- Published in:
- European Heart Journal, 2010, v. 31, n. 6, p. 667
- By:
- Publication type:
- Article
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
- Published in:
- European Heart Journal, 2009, v. 30, n. 19, p. 2337
- By:
- Publication type:
- Article
Unprotected left main revascularization in patients with acute coronary syndromes.
- Published in:
- European Heart Journal, 2009, v. 30, n. 19, p. 2308
- By:
- Publication type:
- Article
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.
- Published in:
- European Heart Journal, 2009, v. 30, n. 19, p. 2318
- By:
- Publication type:
- Article
One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis.
- Published in:
- JAMA: Journal of the American Medical Association, 2007, v. 297, n. 11, p. 1197, doi. 10.1001/jama.297.11.1197
- By:
- Publication type:
- Article
Do patients benefit from omega-3 fatty acids?
- Published in:
- Cardiovascular Research, 2023, v. 119, n. 18, p. 2884, doi. 10.1093/cvr/cvad188
- By:
- Publication type:
- Article
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 1093, doi. 10.1002/ejhf.3240
- By:
- Publication type:
- Article
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
- Published in:
- European Journal of Preventive Cardiology, 2024, v. 31, n. 10, p. e75, doi. 10.1093/eurjpc/zwae110
- By:
- Publication type:
- Article
Omega-3 fatty acids for cardiovascular event lowering.
- Published in:
- European Journal of Preventive Cardiology, 2024, v. 31, n. 8, p. 1005, doi. 10.1093/eurjpc/zwae003
- By:
- Publication type:
- Article
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
- Published in:
- European Journal of Preventive Cardiology, 2022, v. 29, n. 14, p. 1842, doi. 10.1093/eurjpc/zwac107
- By:
- Publication type:
- Article
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEYOUTCOMES trial.
- Published in:
- European Journal of Preventive Cardiology, 2021, v. 28, n. 1, p. 33, doi. 10.1177/2047487320941987
- By:
- Publication type:
- Article
Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease.
- Published in:
- European Journal of Preventive Cardiology, 2020, v. 27, n. 4, p. 426, doi. 10.1177/2047487319871217
- By:
- Publication type:
- Article
Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis.
- Published in:
- European Journal of Preventive Cardiology, 2014, v. 21, n. 12, p. 1531, doi. 10.1177/2047487313500541
- By:
- Publication type:
- Article
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
- Published in:
- Clinical Cardiology, 2017, v. 40, n. 3, p. 138, doi. 10.1002/clc.22692
- By:
- Publication type:
- Article
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
- Published in:
- Clinical Cardiology, 2016, v. 39, n. 10, p. 555, doi. 10.1002/clc.22572
- By:
- Publication type:
- Article
Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry.
- Published in:
- Clinical Cardiology, 2013, v. 36, n. 12, p. 721, doi. 10.1002/clc.22217
- By:
- Publication type:
- Article
Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.
- Published in:
- Clinical Cardiology, 2012, v. 35, n. 12, p. 722, doi. 10.1002/clc.22032
- By:
- Publication type:
- Article
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
- Published in:
- Journal of the American Heart Association, 2023, v. 12, n. 5, p. 1, doi. 10.1161/JAHA.121.026756
- By:
- Publication type:
- Article
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
- Published in:
- 2022
- By:
- Publication type:
- journal article
HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.
- Published in:
- Journal of the American Heart Association, 2018, v. 7, n. 16, p. 1, doi. 10.1161/JAHA.118.009217
- By:
- Publication type:
- Article
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 4, p. 465, doi. 10.1007/s40262-021-01090-2
- By:
- Publication type:
- Article
β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2012, v. 308, n. 13, p. 1340, doi. 10.1001/jama.2012.12559
- By:
- Publication type:
- Article
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis.
- Published in:
- JAMA: Journal of the American Medical Association, 2010, v. 304, n. 12, p. 1350, doi. 10.1001/jama.2010.1322
- By:
- Publication type:
- Article
Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease.
- Published in:
- Vascular Medicine, 2011, v. 16, n. 5, p. 323, doi. 10.1177/1358863X11419997
- By:
- Publication type:
- Article
Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.
- Published in:
- Vascular Medicine, 2010, v. 15, n. 4, p. 259, doi. 10.1177/1358863X10373299
- By:
- Publication type:
- Article
Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.
- Published in:
- European Heart Journal, 2018, v. 39, n. 24, p. 2255, doi. 10.1093/eurheartj/ehx809
- By:
- Publication type:
- Article
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
- Published in:
- European Heart Journal, 2018, v. 39, n. 19, p. 1726, doi. 10.1093/eurheartj/ehy162
- By:
- Publication type:
- Article
Themanagement of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum.
- Published in:
- European Heart Journal, 2017, v. 38, n. 47, p. 3488, doi. 10.1093/eurheartj/ehx531
- By:
- Publication type:
- Article
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
- Published in:
- European Heart Journal, 2016, v. 37, n. 14, p. 1122, doi. 10.1093/eurheartj/ehv498
- By:
- Publication type:
- Article
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
- Published in:
- European Heart Journal, 2015, v. 36, n. 29, p. 1901, doi. 10.1093/eurheartj/ehv116
- By:
- Publication type:
- Article
High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.
- Published in:
- European Heart Journal, 2015, v. 36, n. 16, p. 976, doi. 10.1093/eurheartj/ehu357
- By:
- Publication type:
- Article
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.
- Published in:
- European Heart Journal, 2014, v. 35, n. 41, p. 2864, doi. 10.1093/eurheartj/ehu080
- By:
- Publication type:
- Article
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
- Published in:
- European Heart Journal, 2014, v. 35, n. 40, p. 2812
- By:
- Publication type:
- Article
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
- Published in:
- European Heart Journal, 2014, v. 35, n. 29, p. 1932
- By:
- Publication type:
- Article